Evidence map›Paper›PMID 35887633›Full record

ReviewJournal of personalized medicine2022

Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.

Elena-Georgiana Dobre, Carolina Constantin, Monica Neagu

Open access · goldAbstract readReview
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elena-Georgiana DobreFaculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania.ORCID 0000-0002-6464-381X
Carolina ConstantinImmunology Department, "Victor Babes" National Institute of Pathology, 050096 Bucharest, Romania.ORCID 0000-0002-2870-5497
Monica NeaguFaculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania.ORCID 0000-0001-9339-2805
University of Bucharest · ROInstitutul National Victor Babes · RO

Funding

grant NASR grant NASR, [PN 19.29.01.01]The Romanian Executive Agency for Higher Education, Research, Development and Innovation Funding PN-III-P4-PCE-2021-0549
6 · The paper itself

Abstract

Skin cancer, which includes the most frequent malignant non-melanoma carcinomas (basal cell carcinoma, BCC, and squamous cell carcinoma, SCC), along with the difficult to treat cutaneous melanoma (CM), pose important worldwide issues for the health care system. Despite the improved anti-cancer armamentarium and the latest scientific achievements, many skin cancer patients fail to respond to therapies, due to the remarkable heterogeneity of cutaneous tumors, calling for even more sophisticated biomarker discovery and patient monitoring approaches. Droplet digital polymerase chain reaction (ddPCR), a robust method for detecting and quantifying low-abundance nucleic acids, has recently emerged as a powerful technology for skin cancer analysis in tissue and liquid biopsies (LBs). The ddPCR method, being capable of analyzing various biological samples, has proved to be efficient in studying variations in gene sequences, including copy number variations (CNVs) and point mutations, DNA methylation, circulatory miRNome, and transcriptome dynamics. Moreover, ddPCR can be designed as a dynamic platform for individualized cancer detection and monitoring therapy efficacy. Here, we present the latest scientific studies applying ddPCR in dermato-oncology, highlighting the potential of this technology for skin cancer biomarker discovery and validation in the context of personalized medicine. The benefits and challenges associated with ddPCR implementation in the clinical setting, mainly when analyzing LBs, are also discussed.

Indexed as

biomarkerscutaneous melanomaddPCRimmunotherapyliquid biopsypersonalized medicineskin cancersquamous cell carcinomatargeted therapy

Identifiers

PMID35887633
PMCPMC9323323
OpenAlexW4285496617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.